Flavonoid Supplement Shows Promise for Cognitive Function in Elderly Adults
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
20 articles
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
Eight-week mindfulness program tested for women experiencing severe menopause symptoms after preventive ovary removal surgery.
UC San Diego researchers tested psilocybin's safety and potential benefits for eating disorder symptoms in 16 participants with anorexia nervosa.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Clinical trial explores whether resetting gut microbiome through fecal transplants can slow Parkinson's progression and reduce symptoms.
Small trial tests psychedelic therapy combined with meditation for frontline healthcare providers suffering COVID-related burnout.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
King's College study tests whether simple chewing and fasting patterns can enhance cognitive function and neurogenesis in older adults.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
Pilot study tests psilocybin-assisted psychotherapy to help hospice patients overcome demoralization and existential suffering.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Combining Mediterranean-DASH diet with nature therapy targets hypertension and cognitive decline in older adults.
60-person study tested psilocybin alone and with CBT for major depression, measuring brain activity and inflammatory markers.